Major Program
              Supportive Care and Symptom Management
              NCI Community Oncology Research Program
                    Research Group
              Community Oncology and Prevention Trials
                    Sponsor
                    Alliance for Clinical Trials in Oncology
                Status
                    Completed
                NCT ID
                    NCT02116530
                This randomized phase III trial studies antiemetic therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by blocking brain receptors that appear to be involved in nausea and vomiting.
            
  
  
      Intervention
                    Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Olanzapine, Placebo
                Condition
                    Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
                Investigators
                    Rudolph M. Navari, MD, PhD, FACP
                